Immatics N.V Dossier
Qualitative Analysis
Business overview
Immatics N.V. (NASDAQ: IMTX) is a clinical-stage biopharmaceutical company incorporated in the Netherlands, with its main operational assets and activities conducted through its German subsidiary, Immatics Biotechnologies GmbH, based in Tübingen. The company is a pioneer in the discovery and development of T-cell receptor (TCR)-based immunotherapies designed to target intracellular cancer antigens, which are typically inaccessible to traditional antibody or CAR-T therapies. Immatics operates through two primary therapeutic modalities: Adoptive Cell Therapies (ACTengine and ACTallo autologous and allogeneic platforms) and TCR Bispecifics (TCER). Its proprietary target discovery platform, XPRESIDENT, and bioinformatics engine, XCUBE, enable the identification of highly specific tumor-associated peptides, establishing a robust pipeline led by its clinical-stage PRAME-targeting franchise.
Research as of 20 Jun 2026
Strategic Initiatives
Growth programs, investments, and their expected impact
Simultaneously advancing precision targeting of PRAME across two distinct therapeutic modalities: adoptive cell therapies (anzu-cel and second-generation IMA203CD8) and TCR bispecifics (IMA402).
Expected impact: Establishes Immatics as the global leader in PRAME-targeted oncology therapies across multiple solid tumor indications.
Collaborating with Cellular Origins to integrate their automated mobile robotic platform, Constellation, into Immatics' cell therapy manufacturing processes.
Expected impact: Enables scalable, cost-effective, and high-throughput manufacturing of autologous cell therapies to support future commercialization.
Mergers, Acquisitions & Partnerships
Recent deals and strategic collaborations
Strategic Partnerships
Aims to develop novel mRNA-based cancer vaccines and evaluate combination therapies. In December 2025, Moderna advanced the first mRNA-based TCER product candidate into clinical development, triggering a regulatory milestone payment to Immatics in January 2026.
Terms: Immatics received $120 million upfront, with potential milestone payments exceeding $1.7 billion plus royalties. Moderna fully reimburses all Phase 1 clinical trial costs conducted by Immatics.
The initial 2019 collaboration for T-cell receptor therapies remains ongoing, providing external validation of Immatics' platform. Note that BMS terminated separate cell therapy contracts (IMA401 and ACTallo) in late 2024 as part of its corporate portfolio prioritization.
Terms: The initial 2019 deal included a $75 million upfront payment with potential licensing and milestone payments up to $1.5 billion.